Literature DB >> 15923109

Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.

Hyukjin Cha1, Surabhi Dangi, Carolyn E Machamer, Paul Shapiro.   

Abstract

The mixed-lineage kinases (MLK) are serine/threonine protein kinases that regulate mitogen-activated protein (MAP) kinase signaling pathways in response to extracellular signals. Recent studies indicate that MLK activity may promote neuronal cell death through activation of the c-Jun NH2-terminal kinase (JNK) family of MAP kinases. Thus, inhibitors of MLK activity may be clinically useful for delaying the progression of neurodegenerative diseases, such as Parkinson's. In proliferating non-neuronal cells, MLK may have the opposite effect of promoting cell proliferation. In the current studies we examined the requirement for MLK proteins in regulating cell proliferation by examining MLK function during G2 and M-phase of the cell cycle. The MLK inhibitor CEP-11004 prevented HeLa cell proliferation by delaying mitotic progression. Closer examination revealed that HeLa cells treated with CEP-11004 during G2-phase entered mitosis similar to untreated G2-phase cells. However, CEP-11004 treated cells failed to properly exit mitosis and arrested in a pro-metaphase state. Partial reversal of the CEP-11004 induced mitotic arrest could be achieved by overexpression of exogenous MLK3. The effects of CEP-11004 treatment on mitotic events included the inhibition of histone H3 phosphorylation during prophase and prior to nuclear envelope breakdown and the formation of aberrant mitotic spindles. These data indicate that MLK3 might be a unique target to selectively inhibit transformed cell proliferation by disrupting mitotic spindle formation resulting in mitotic arrest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923109      PMCID: PMC2835151          DOI: 10.1016/j.cellsig.2005.03.028

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  35 in total

Review 1.  Phosphorylation of serine 10 in histone H3, what for?

Authors:  Claude Prigent; Stefan Dimitrov
Journal:  J Cell Sci       Date:  2003-09-15       Impact factor: 5.285

Review 2.  Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis.

Authors:  Gaetan Pascreau; Yannick Arlot-Bonnemains; Claude Prigent
Journal:  Prog Cell Cycle Res       Date:  2003

3.  Cell cycle arrest by Colcemid differs in human normal and tumor cells.

Authors:  M N Jha; J R Bamburg; J S Bedford
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

4.  MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation.

Authors:  Deborah N Chadee; John M Kyriakis
Journal:  Nat Cell Biol       Date:  2004-07-18       Impact factor: 28.824

5.  Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.

Authors:  Hua Zhang; Wei Wu; Yan Du; Sarah J Santos; Susan E Conrad; Jack T Watson; Nicholas Grammatikakis; Kathleen A Gallo
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

6.  Phosphorylation of golgin-160 by mixed lineage kinase 3.

Authors:  Hyukjin Cha; Barbara L Smith; Kathleen Gallo; Carolyn E Machamer; Paul Shapiro
Journal:  J Cell Sci       Date:  2004-01-20       Impact factor: 5.285

7.  Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies.

Authors:  Hyukjin Cha; Chad Hancock; Surabhi Dangi; Dony Maiguel; France Carrier; Paul Shapiro
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

8.  A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.

Authors:  Yong-Yeon Cho; Ann M Bode; Hideya Mizuno; Bu Young Choi; Hong Seok Choi; Zigang Dong
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 9.  Mixed-lineage kinases: a target for the prevention of neurodegeneration.

Authors:  Leo H Wang; Cagri G Besirli; Eugene M Johnson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

10.  Cloning and characterization of MST, a novel (putative) serine/threonine kinase with SH3 domain.

Authors:  M Katoh; M Hirai; T Sugimura; M Terada
Journal:  Oncogene       Date:  1995-04-06       Impact factor: 9.867

View more
  5 in total

Review 1.  Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity?

Authors:  Matthew E Handley; Jane Rasaiyaah; Benjamin M Chain; David R Katz
Journal:  Int J Exp Pathol       Date:  2007-04       Impact factor: 1.925

Review 2.  Mixed Lineage Kinase-c-Jun N-Terminal Kinase Axis: A Potential Therapeutic Target in Cancer.

Authors:  Ajay Rana; Basabi Rana; Rajakishore Mishra; Gautam Sondarva; Velusamy Rangasamy; Subhasis Das; Navin Viswakarma; Anumantha Kanthasamy
Journal:  Genes Cancer       Date:  2013-09

3.  Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.

Authors:  M R Cronan; K Nakamura; N L Johnson; D A Granger; B D Cuevas; J-G Wang; N Mackman; J E Scott; H G Dohlman; G L Johnson
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

4.  Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells.

Authors:  Claudia Urueña; Claudia Cifuentes; Diana Castañeda; Amparo Arango; Punit Kaur; Alexzander Asea; Susana Fiorentino
Journal:  BMC Complement Altern Med       Date:  2008-11-18       Impact factor: 3.659

5.  Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.

Authors:  Limin Wang; Kathleen A Gallo; Susan E Conrad
Journal:  Oncotarget       Date:  2013-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.